350 related articles for article (PubMed ID: 29751505)
1. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.
Schilling S; Rahfeld JU; Lues I; Lemere CA
Molecules; 2018 May; 23(5):. PubMed ID: 29751505
[TBL] [Abstract][Full Text] [Related]
2. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ; Liu B; Frost JL; Lemere CA
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.
Liu J; Yang B; Ke J; Li W; Suen WC
Drugs Aging; 2016 Oct; 33(10):685-697. PubMed ID: 27699633
[TBL] [Abstract][Full Text] [Related]
5. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
6. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.
Lathuilière A; Laversenne V; Astolfo A; Kopetzki E; Jacobsen H; Stampanoni M; Bohrmann B; Schneider BL; Aebischer P
Brain; 2016 May; 139(Pt 5):1587-604. PubMed ID: 26956423
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
8. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
9. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.
Montoliu-Gaya L; Villegas S
Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999
[TBL] [Abstract][Full Text] [Related]
10. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Rygiel K
Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
[TBL] [Abstract][Full Text] [Related]
12. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML
Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
14. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
15. Immunological approach for the treatment of Alzheimer's disease.
Solomon B
J Mol Neurosci; 2003; 20(3):283-6. PubMed ID: 14501009
[TBL] [Abstract][Full Text] [Related]
16. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM
Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Li Y; Liu Y; Wang Z; Jiang Y
Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
[TBL] [Abstract][Full Text] [Related]
18. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
[TBL] [Abstract][Full Text] [Related]
19. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
20. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer.
Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K
Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
